FAQs - Myriad tests

Approximately 1 in 4 patients in the community OBGYN setting may be at risk for hereditary cancer and meet current screening guidelines for testing. Screening and subsequent interventions have been shown to reduce risk.

Myriad offers three different categories of testing for women: cancer risk assessment with MyRisk, inherited conditions for family planning with ForeSight, and prenatal screening with Prequel.

What Prolaris measures is not whether you have prostate cancer, but how fast your cancer cells are dividing, or its aggressiveness. Getting a Prolaris Score will tell your doctor additional information about your cancer.

Any patient diagnosed with prostate cancer is a good candidate for Prolaris testing. Since all men with prostate cancer have already received a prostate biopsy, there is no need to undergo any additional biopsies in order to get testing with Prolaris.

The Prolaris test from Myriad Genetics gives a personalized risk assessment of a patients’ prostate cancer. Prolaris gives the complete picture on how a patient’s prostate cancer will progress by adding clinically proven information in combination with traditional diagnostic tools.

If your screen turns up something unusual, your healthcare provider will discuss what it means and will offer a follow-up diagnostic procedure to confirm the results. This may be chorionic villus sampling (CVS) or amniocentesis.

Patients can use Prequel as early as ten weeks into their pregnancy to identify an increased risk for a chromosome abnormality associated with a certain genetic condition.

The Myriad Prequel Prenatal Screen is a noninvasive screen ordered by your healthcare provider when you are pregnant to learn about your baby’s chance of having a chromosome abnormality leading to a condition like Down syndrome.

MyChoice CDx identifies ~34% more tumors with HRD than %LOH alone.

Homologous recombination (HR) is the way our body fixes damaged DNA. When homologous recombination is not able to fix damaged DNA, this is called homologous recombination deficiency (HRD). Approximately 50% of all ovarian cancer tumors have homologous recombination deficiency.

MyChoice CDx is the first and only FDA-approved tumor test that determines HRD status using BRCA status and Genomic Instability Status. It is the most comprehensive tumor test to determine HRD status in patients with ovarian cancer.

BRACAnaysis CDx is the only FDA-targeted therapy used to detect mutations in BRCA1 or BRCA2 genes. Mutations in these genes can influence breast cancer, ovarian cancer, pancreatic cancer, and prostate cancer. Early detection can help you and your healthcare provider the best healthcare decisions for your future care.

BRACAnalysis tests for a mutation in specific genes to determine hereditary breast or ovarian cancer risk.

MyRisk and MyScore work together to provide information on hereditary cancer genes, personal and family history, breast cancer genetic risk markers, and ancestry genetic risk markers.

RiskScore is the only breast cancer risk assessment test that incorporates the patient’s own clinical risk factors, family history, and unique genetic, ancestry-informed breast cancer risk markers.